The publication of this infographic was funded by Almirall, and is based on an Almirall sponsored study.
The POSITIVE Phase IV Study: Interim 52-Week Results on Patient Well-Being With Tildrakizumab
Dermatology
Introduction
Psoriatic disease is a chronic inflammatory condition, with a complex pathophysiology, affecting approximately 2% of the global population.1,2
Traditionally, plaque psoriasis has been assessed primarily through assessment of skin (PASI, BSA, PGA) and health-related quality of life (DLQI).7–10
1. Damiani G et al. Front Med (Lausanne). 2021;8:743180.
2. Deng Y et al. Clin Rev Allergy Immunol. 2016;50(3):377-89.
3. Krueger G et al. Arch Dermatol. 2001;137(3):280-4.
4. Bhosle MJ et al. Health Qual Life Outcomes. 2006;4:35.
5. Langley RGB et al. Ann Rheum Dis. 2005;64 Suppl 2(Suppl 2):ii18-23; discussion ii24-25.
6. Armstrong AW et al. PLoS One. 2012;7(12):e52935.
7. Twiss J et al. J Invest Dermatol. 2012;132(1):76-84.
8. Langenbruch A et al. J Eur Acad Dermatol Venereol. 2019;33(1):123-7.
9. Abrouk M et al. J Dermatolog Treat. 432 2017;28(6):488-91.
10. Kirsten N et al. Life (Basel). 2021;11(11):1151.
11. Ständer S, Thaçi D. J Dermatolog Treat. 2025;36(1):2438803
12. Augustin M, et al. BMJ Open. 2023;13(2):e060536.
13. Mroweitz et al. Psoriasis (Auckl). 2025;15:243-59.
14. Eurofound. European Quality of Life Survey - Data visualisation. Available at: https://www.eurofound.europa.eu/en/data-catalogue/eur%20pean-%20quality-life-survey.%20Last%20accessed:%2015%20August%202025.
15. Pintaudi B et al. J Psychosom Res. 2015;79(5):348-54.
16. Hoffman CJ et al. J Clin Oncol. 2012;30(12):1335-42.
17. Almirall. ILUMETRI® (tildrakizumab) PRESCRIBING INFORMATION. Available at: https://dermatology.almirallmed.co.uk/wp-content/uploads/sites/16/2024/03/UKIE-Ilumetri-PI-Feb2024_v4.pdf. Last accessed: 2 September 2025.
References
Abbreviations: DLQI-R: Dermatology Life Quality Index questionnaire-Relevant; HRQOL: Health Related Quality of Life; LOCF: last observation carried forward; MI: multiple imputation; NRS: Numeric Rating Scale; OC: observed cases; PASI: Psoriasis Area and Severity Index; PGA: Physicians Global Assessment; TSQM-9, Treatment satisfaction questionnaire 9, WHO: World heatlh organisation; WPAI: Work Productivity and Activity Impairment Questionnaire; WHO-5: the 5-item WHO Well-being Index.
Acknowledgements: Medical writing assistance provided by Tom Gurney, Jessica Jinks & Yolande Chalmers, EMJ, London, UK
Created by Richard Neighbour.
Abbreviations
References & Abbreviations
UK-TIL-2500003 September 2025
This material is intended for HCPs. UK Prescribing Information for Tildrakizumab can be found here, and Adverse Event Reporting Information can be found at the end of this infographic.
For HCPs outside of the UK, please refer to your local guidelines, as information may vary.
Beyond its physical symptoms, psoriatic disease imposes a significant psychosocial burden, often leading to embarrassment, social withdrawal, and low self-esteem.3,4
Anxiety and depression are also commonly associated with psoriatic disease and may contribute to reduced overall psychological well-being.4-6, though the relationship may be bidirectional.
However, clinical severity alone may not fully capture the true burden of the disease, underscoring the importance of more holistic approaches to evaluation.10
Tildrakizumab is an interleukin (IL)-23p19 inhibitor approved for the treatment of adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy, offering sustained disease control as demonstrated in both clinical trials and real-world studies.11
MEthODS
The POSITIVE study12 is a 24-month observational study, which takes a patient-centric approach to demonstrating the wider impact of psoriatic disease on the well-being of patients, their families, and healthcare professionals.12
INTERIM OUTCOMES
Conclusion/ Key Learnings
Tildrakizumab contributes to a holistic healthcare approach for moderate-to-severe psoriatic disease through:13
Tildrakizumab contributes to a holistic healthcare approach for moderate-to-severe psoriatic disease through:13
Improved psychological well-being assessed with the WHO-5 index
Improvement of HRQoL assessed by DLQI-R.
Reduced burden on family assessed with the Family PsO
Skin clearance as measured by PASI and clearance of psoriasis in high impact areas
Reduction of symptoms as measured by the pruritus-, pain-, joint pain-, and fatigue-NRS
Tildrakizumab improves clinical outcomes, without any new safety signals.13,17
Safety outcomes: 24% of patients had ≤1 AE (most commonly infections [12.3%], COVID-19 [4.0%], and nasopharyngitis [3.0%]). Only one treatment-related AE led to discontinuation.13